Want to see WVE full AI Analyst Report?

Wave Life Sciences (WVE) Price & Analysis

1,447 Followers

WVE Stock Chart & Stats

$7.49

-$0.07(-0.54%)

At close: Jan 08 4:00 PM EST

$7.49

-$0.07(-0.54%)

Day’s Range― - ―

52-Week Range$5.02 - $21.73

Previous CloseN/A

Volume104.35K

Average Volume (3M)3.84M

Market Cap

$1.20B

Enterprise Value$615.92M

Total Cash (Recent Filing)$544.59M

Total Debt (Recent Filing)$15.71M

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Jul 30, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding192,402,200

10 Day Avg. Volume3,430,210

30 Day Avg. Volume3,838,505

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)5.45

Price to Sales (P/S)67.10

P/FCF Ratio-15.29

Enterprise Value/Market Cap0.51

Enterprise Value/Revenue8.58

Enterprise Value/Gross Profit9.15

Enterprise Value/Ebitda-3.53

Forecast

1Y Price Target

$23.75

Price Target Upside217.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-1.11

Revenue Forecast (FY)$58.25M

Bulls Say, Bears Say

Bulls Say

Cash RunwayA multi-year cash runway materially reduces near-term financing pressure and gives management time to execute multiple mid-stage readouts and regulatory interactions. This durable liquidity supports clinical advancement and strategic optionality without immediate dilution if milestones proceed as planned.

WVE-006 RNA EditingRobust, dose-dependent restoration of functional M‑AAT and large reductions in toxic Z‑AAT with sustained editing and a favorable safety profile indicate a differentiated therapeutic profile. This durable biomarker and safety signal supports potential regulatory pathways and a lasting position in AATD treatment if confirmed in pivotal studies.

WVE-007 Obesity SignalA durable body‑composition signal that preserves muscle and reduces visceral fat supports a clear clinical differentiation versus existing weight-loss agents. Acceptance of the Phase IIa multidose portion and plans for combination/maintenance studies create a lasting strategic pathway for positioning WVE‑007 in obesity and cardiometabolic care.

Bears Say

High Cash BurnSustained negative operating and free cash flow at this magnitude creates ongoing funding dependence beyond milestone variability. Even with a multi-year runway, persistent high burn increases likelihood of future equity raises or partnerships, which can dilute shareholders and complicate long-term planning if program timelines slip.

Large Operating LossesDeep, persistent operating losses mean current revenues do not cover the cost base and the company lacks profitability leverage. This structural unprofitability constrains reinvestment capacity and raises execution risk for commercial-scale activities unless cost structures shift or recurrent product revenue emerges.

Regulatory & Competitive RiskPending regulator decisions on endpoints and accelerated pathways create material execution risk; ambiguous regulatory expectations can force larger or altered trials. Simultaneously, competing modalities reporting comparable biomarker gains raise the bar for differentiation, potentially reducing market share even if technical success is achieved.

Wave Life Sciences News

Wave Life Sciences initiates multidose portion of Inlight trial

Wave Life Sciences (WVE) announced it has initiated the Phase 2a multidose portion of the Inlight trial, a...

12d ago

WVE

Wave Life Sciences Shareholders Approve Redomiciliation Scheme

An update from Wave Life Sciences ( ($WVE) ) is now available. On June 22, 2026, Wave Life...

10d ago

WVE

Wave Life Sciences: Buy Rating Reiterated on Differentiated Obesity Profile; $13 Price Target Unchanged

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating on...

25d ago

WVE

Acting FDA head vows to block political interference, Endpoint News says

Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas and senior staff....

1M ago

AZN

BMY

FDA issues draft guidance to help accelerated cell, gene therapies for patients

The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene...

1M ago

AZN

BMY

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts

High‑risk, high‑reward stocks are companies whose share prices can witness large swings, either up or down, as their...

1M ago

WVE

REAX

Wave Life Sciences price target raised to $14 from $13 at Wells Fargo

Wells Fargo raised the firm’s price target on Wave Life Sciences (WVE) to $14 from $13 and keeps...

2M ago

WVE

Wave Life Sciences Signals Momentum in Earnings Call

Wave Life Sciences Pte. Ltd (($WVE)) has held its Q1 earnings call. Read on for the main highlights...

2M ago

WVE

Wave Life Sciences price target lowered to $13 from $18 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Wave Life Sciences (WVE) to $13 from $18 and keeps...

2M ago

WVE

Wave Life Sciences: Buy Rating Reaffirmed as WVE-006 Data Strengthen Case for Accelerated Pathway; $15 Price Target Maintained

Analyst Yun Zhong of Wedbush maintained a Buy rating on Wave Life Sciences, retaining the price target of...

2M ago

WVE

Wave Life Sciences advances WVE-006 RNA editing trial

Wave Life Sciences ( ($WVE) ) has issued an announcement. On May 18, 2026, Wave Life Sciences reported...

2M ago

WVE

Wave Life Sciences announces updated data from RestorAATion-2 trial of WVE-006

Wave Life Sciences (WVE) announced updated data from the ongoing RestorAATion-2 trial of WVE-006, its investigational, GalNAc-conjugated, subcutaneously...

2M ago

WVE

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2M ago

AZN

BMY

Trump Trade: U.S. plans AI security order without required model tests

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2M ago

DYN

RNA

WVE FAQ

What was Wave Life Sciences Pte. Ltd’s price range in the past 12 months?

Wave Life Sciences Pte. Ltd lowest stock price was $5.02 and its highest was $21.73 in the past 12 months.

What is Wave Life Sciences Pte. Ltd’s market cap?

Wave Life Sciences Pte. Ltd’s market cap is $1.20B.

When is Wave Life Sciences Pte. Ltd’s upcoming earnings report date?

Wave Life Sciences Pte. Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 24 days.

How were Wave Life Sciences Pte. Ltd’s earnings last quarter?

Wave Life Sciences Pte. Ltd released its earnings results on Apr 28, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.194.

Is Wave Life Sciences Pte. Ltd overvalued?

According to Wall Street analysts Wave Life Sciences Pte. Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wave Life Sciences Pte. Ltd pay dividends?

Wave Life Sciences Pte. Ltd does not currently pay dividends.

What is Wave Life Sciences Pte. Ltd’s EPS estimate?

Wave Life Sciences Pte. Ltd’s EPS estimate is -0.3.

How many shares outstanding does Wave Life Sciences Pte. Ltd have?

Wave Life Sciences Pte. Ltd has 192,402,200 shares outstanding.

What happened to Wave Life Sciences Pte. Ltd’s price movement after its last earnings report?

Wave Life Sciences Pte. Ltd reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went up 8.357%.

Which hedge fund is a major shareholder of Wave Life Sciences Pte. Ltd?

Currently, no hedge funds are holding shares in WVE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wave Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-56.41%

Trailing 12-Months

Asset Growth

102.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wave Life Sciences Pte. Ltd

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Wave Life Sciences (WVE) Earnings & Revenues

Historic Earnings Reports

WVE Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed substantial positive momentum: meaningful revenue growth (largely license-related), improved net loss, strong cash runway, and multiple encouraging clinical readouts and development milestones (notably WVE-007 visceral fat and VMR improvements, advancing WVE-007 into Phase IIa, and WVE-006 demonstrating therapeutically relevant MAAT and regulatory path potential). Headwinds include rising operating expenses, remaining net losses, regulatory and competitive uncertainties, and the need for careful patient enrichment for 007 trials. On balance, the operational and clinical progress and capitalization materially outweigh the listed challenges, but execution risk and competitive dynamics remain important near-term considerations.View all WVE earnings summaries

WVE Stock 12 Month Forecast

Average Price Target

$23.75

▲(217.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","14":"$14","24":"$24","34":"$34","44":"$44"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$43.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,14,24,34,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.84,8.698461538461538,11.556923076923077,14.415384615384614,17.27384615384615,20.13230769230769,22.990769230769228,25.84923076923077,28.707692307692305,31.566153846153842,34.42461538461538,37.28307692307692,40.14153846153846,{"y":43,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.84,7.217692307692308,8.595384615384615,9.973076923076924,11.350769230769231,12.728461538461538,14.106153846153846,15.483846153846155,16.861538461538462,18.23923076923077,19.61692307692308,20.994615384615386,22.372307692307693,{"y":23.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.84,6.390769230769231,6.941538461538461,7.492307692307692,8.043076923076923,8.593846153846155,9.144615384615385,9.695384615384615,10.246153846153845,10.796923076923077,11.347692307692308,11.89846153846154,12.44923076923077,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.515,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >